UNSPSC 85813105: Introduction of analgesics, hypnotics, sedatives into biliary and pancreatic tract, via natural or artificial opening endoscopic

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of analgesics, hypnotics, sedatives into biliary and pancreatic tract, via natural or artificial opening endoscopic. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0J8NZ

UNSPSC 85813105 Introduction of analgesics, hypnotics, sedatives into biliary and pancreatic tract, via natural or artificial opening endoscopic is a Commodity code that shows little relevant recent activity under state and local procurement. The code nominally describes a highly specialized endoscopic pharmaceutical procedure, yet the recent opportunities tagged to it span virtual urgent care services, general medical services, occupational health services, employee wellness platforms, and behavioral health programming—none of which align with the code's clinical scope of analgesic or sedative introduction via endoscopic biliary or pancreatic access. The mismatch between code taxonomy and actual procurement activity suggests either tagging error or that this Commodity code remains dormant in state and local contracting workflows.

The source contains no solicitations that match the code's intended scope. Issuers span health plans (Inland Empire Health Plan in California), county health systems (DeKalb County, Georgia and Santa Clara County, California), state health authorities (Nevada Health Authority), and behavioral health departments, but none are soliciting endoscopic pharmaceutical services. Geographic spread encompasses California, Georgia, Nevada, Florida, Colorado, Arizona, and several other states, though this reflects the diversity of the unrelated opportunities rather than concentration within the code itself. Without representative endoscopic pharmaceutical opportunities in the recent record, practitioners evaluating this code should treat it as inactive in current state and local markets and focus business development efforts on codes with active, aligned solicitation flow.